EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond Newborn Screening: Clinical Outcomes and Genotypic Spectrum Underlying Maple Syrup Urine Disease in Mexico

Marcela Vela-Amieva iD, Miriam Erandi Reyna-Fabián iD, Liliana Fernández-Hernández iD, Sara Guillén-López iD, Lizbeth López-Mejía iD, Miguel Angel Alcantara-Ortigoza iD, Ariadna Gonzalez-Del Angel iD, Bernardette Estandía-Ortega, Isabel Ibarra-González iD, Laura Paz-Castillo, Cynthia Fernández-Lainez iD

International Journal of Neonatal Screening · 09.10.2026 · 12 (4) · 83

DOI: 10.3390/ijns12040083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 09.10.2026. Verfasst von Marcela Vela-Amieva und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional de Pediatria, National Institute of Pediatrics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maple syrup urine disease (MSUD) is a time-critical inborn error of metabolism in which early detection may prevent irreversible neurological injury, yet the success of newborn screening (NBS) depends on timely post-screening care. We retrospectively characterized the clinical, biochemical, and genotypic spectrum of 88 Mexican patients from 80 unrelated families evaluated between 1995 and 2026 and assessed the relationship between NBS, treatment timing, neurological outcome, and survival. Most patients had severe neonatal disease, and 73/88 (83%) presented with acute metabolic decompensation requiring hospitalization. Nine patients were identified by NBS: six received timely confirmatory diagnosis and treatment and maintained normal age-appropriate neurodevelopment during 10 years of follow-up, whereas three experienced delays in the diagnostic and therapeutic pathway, developed metabolic decompensation, and subsequently had severe neurological disability. None of the successfully screened patients died. Among 33 molecularly characterized unrelated patients, 31 distinct variants were identified in BCKDHA, BCKDHB, and DBT, with marked genotypic heterogeneity. These findings show that National NBS strategies should prioritize the inclusion of this time critical disorder and the shortening of the interval between a positive screening result and treatment initiation. MSUD NBS should serve as the entry point to an optimal continuum of care. Rapid confirmation, immediate referral, treatment initiation, and sustained specialized metabolic follow-up are essential for translating early detection into favorable outcomes.

Schlagwörter

Stichwörter der Autor:innen

newborn screeningpost-screeningpublic healthshort and long-term follow-up

Autor:innen und Institutionen

  • Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.
  • Laboratorio de Biología Molecular, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.
  • Unidad de Genética de la Nutrición, Instituto de Investigaciones Biomédicas, National Autonomous University of Mexico (UNAM), Mexico City 04530, Mexico.
  • Servicio de Endocrinología, Hospital de la Niñez Oaxaqueña, Oaxaca 71294, Mexico.

ORCID-Profile: Marcela Vela-Amieva, Miriam Erandi Reyna-Fabián, Liliana Fernández-Hernández, Sara Guillén-López, Lizbeth López-Mejía, Miguel Angel Alcantara-Ortigoza, Ariadna Gonzalez-Del Angel, Isabel Ibarra-González, Cynthia Fernández-Lainez

Förderung

  • Instituto Nacional de Pediatria
  • National Institute of Pediatrics

Zitieren

APA

Vela-Amieva, M., Reyna-Fabián, M. E., Fernández-Hernández, L., Guillén-López, S., López-Mejía, L., Alcantara-Ortigoza, M. A., Gonzalez-Del Angel, A., Estandía-Ortega, B., Ibarra-González, I., Paz-Castillo, L., & Fernández-Lainez, C. (2026). Beyond Newborn Screening: Clinical Outcomes and Genotypic Spectrum Underlying Maple Syrup Urine Disease in Mexico. International Journal of Neonatal Screening, 12(4), 83. https://doi.org/10.3390/ijns12040083

Vancouver

Vela-Amieva M, Reyna-Fabián ME, Fernández-Hernández L, Guillén-López S, López-Mejía L, Alcantara-Ortigoza MA, et al. Beyond Newborn Screening: Clinical Outcomes and Genotypic Spectrum Underlying Maple Syrup Urine Disease in Mexico. International Journal of Neonatal Screening. 2026;12(4):83. doi:10.3390/ijns12040083

BibTeX
@article{VelaAmieva2026,
  author = {Vela-Amieva, Marcela and Reyna-Fabián, Miriam Erandi and Fernández-Hernández, Liliana and Guillén-López, Sara and López-Mejía, Lizbeth and Alcantara-Ortigoza, Miguel Angel and Gonzalez-Del Angel, Ariadna and Estandía-Ortega, Bernardette and Ibarra-González, Isabel and Paz-Castillo, Laura and Fernández-Lainez, Cynthia},
  title = {Beyond Newborn Screening: Clinical Outcomes and Genotypic Spectrum Underlying Maple Syrup Urine Disease in Mexico},
  journal = {International Journal of Neonatal Screening},
  year = {2026},
  volume = {12},
  number = {4},
  pages = {83},
  doi = {10.3390/ijns12040083}
}
Kostenlos starten →